Integration and use of Schistosoma mansoni genomic data towards the identification of candidate therapeutic targets

Adhemar Zerlotini,Mark Heiges,Haiming Wang,Regina Coeli,Romulo Moraes,Anderson Dominitini,Jessica Kissinger,Guilherme Oliveira
2009-01-01
Abstract:Introduction Schistosomiasis is a parasitic disease responsible for more than 200 million infections in 74 developing countries. The present work focuses on the computational genome analysis of the trematode species, S. mansoni. Methods The S. mansoni metabolic pathways database, was created using Pathway tools software[1] developed by SRI International. The Pathway tools software contains algorithms to predict the metabolic pathways of the organism from its genome by comparison to the MetaCyc reference pathways database[2]. It determines the catalyzed reactions based on the gene products obtained from the genome annotation. The construction of a metabolic pathway database allows us to perform a chokepoint analysis to identify potential drug targets. The term 'chokepoint reaction' was coined by Yeh and colleagues[3] referring to reactions that uniquely consume a specific substrate or produce a specific product. Database integration allowed us to identify drugs that have their target characterized in other organisms and therefore may target S. mansoni chokepoints. Four drugs were then chosen to be tested in vivo aiming to evaluate their potential antischistosomal effect, namely Allopurinol, Methotrexate, Pravastatin and Trimethoprim. 60 female Swiss mice (~25g) were infected with 80 ± 10 cercarie of S. mansoni LE and after 40 days groups of 10 mice were treated with each drug. After 10 days, by perfusing the mice, we were able to compare the number of remaining worms of each treated group against a non-treated group and calculate the reduction worm rate[4]. Results SchistoDB [http://schistocyc.schistodb.net][5] was created using PathwayTools software and permitted us to identify 192 chokepoint reactions, i.e. points of interest for drug targeting. These findings propelled us to conduct in vivo tests for drugs with known mechanisms of action. Table 1 summarizes the in vivo drug tests, where we could identify statistically significant reduction of worm rates for two of the tested drugs.
What problem does this paper attempt to address?